NCT07356297尚未招募不适用
Comparing Remotely-delivered Interventions to Promote Cessation Among Adults Who Smoke Menthol Cigarettes
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 1,200
研究概览
简要总结
The purpose of this study is to evaluate whether a digital, incentive-based program, used in conjunction with traditional quitline (QL) services, can be beneficial to quitline callers who smoke menthol cigarettes. The services evaluated focus on coaching, support, and/or incentives for individuals who wish to quit smoking.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adults (ages 18+) who call partnered quitlines (QL); and
- •currently smoke menthol cigarettes; and
- •are fluent in English; and
- •plan to live in the United States for the full trial duration; and
- •have daily smartphone access (including data access) or are willing to use a study-provided smartphone and data plan
- •ability to provide informed consent
排除标准
- •not ready to set a quit date within 30 days; or
- •have not smoked in the past 7 days
- •Inability to speak/understand English
- •Conditions precluding informed consent or understanding of intervention or assessment content
- •PI discretion
研究组 & 干预措施
Quitline (QL)
Active Comparator
Participants complete QL services
干预措施: Quitline (QL) (Behavioral)
Quitline (QL) + App
Active Comparator
Participants complete QL services and download our incentive-based mobile app
干预措施: Quitline (QL) (Behavioral)
Quitline (QL) + App
Active Comparator
Participants complete QL services and download our incentive-based mobile app
干预措施: Mobile incentive-based intervention (Behavioral)
研究者
Lara Coughlin
Principal Investigator
University of Michigan
相似试验
已完成
3 期
Once-A-Day Pregabalin For Partial SeizuresCTRI/2011/08/001976Pfizer Limited264
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety and efficacy of daily 200 mg fluvoxamine as add-on therapy to standard of care in moderate severity COVID-19 patientsSARS-CoV-2 infected patientsMedDRA version: 23.0Level: LLTClassification code 10084270Term: SARS-CoV-2 acute respiratory diseaseSystem Organ Class: 100000004862EUCTR2020-002299-11-HUSigmaDrugs Research Ltd.100
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group, multicenter twoweek study to evaluate the efficacy and safety of once-daily, intranasaladministration of GW685698X aqueous nasal spray 100 mcg in adult andadolescent subjects with seasonal allergic rhinitis in EuropeSeasonal allergic rhinitis (SAR)EUCTR2004-004434-14-SEGlaxoSmithKline Research & Development Ltd288
进行中（未招募）
1 期
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients with Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and are Treated with Insulin (ODYSSEY DM - Insulin)HypercholesterolemiaEUCTR2015-000799-92-ITSANOFI-AVENTIS GROUPE517
进行中（未招募）
不适用
Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (lixisenatide)EUCTR2009-012852-26-LVsanofi-aventis Recherche & Développement6,000